phrykt

aTYR PHARMA INC (ATYR): who owns it and who trades it

As of Nov 16, 2026, ATYR insiders reported 3 open-market sales worth $6.3K and 1 purchase worth $50K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Sanjay Shukla (CEO), with $3.7K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling ATYR Pharma

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ATYR

89 funds and institutions reported ATYR shares worth $24.2M at the end of Q2 2026, about 41% of the company. The largest holder is Federated Hermes, Inc. with 8.7%.

Funds and institutions (13F) 41%Everyone else 59%

10 largest owners, by share of the company

Federated Hermes, Inc.8.7%
Vanguard Capital Management LLC3.9%
Kalehua Capital Management LLC3.6%
Gsa Capital Partners LLP3.5%
AQR Capital Management LLC2.7%
FMR LLC (Fidelity)2.5%
BlackRock, Inc.1.9%
Jane Street Group, LLC1.8%
UBS Group AG1.6%
Morgan Stanley1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Federated Hermes, Inc.8.51M8.68%$5.1M-19%
Vanguard Capital Management LLC3.81M3.88%$2.3M-0%
Kalehua Capital Management LLC3.58M3.65%$2.1M–
Gsa Capital Partners LLP3.45M3.52%$2.1M+105%
AQR Capital Management LLC2.61M2.66%$1.6M+426%
FMR LLC (Fidelity)2.47M2.52%$1.5M-83%
BlackRock, Inc.1.83M1.86%$1.1M-72%
Jane Street Group, LLC1.72M1.76%$1M+3449%
UBS Group AG1.53M1.56%$914K-60%
Morgan Stanley1.34M1.37%$802K+10%
Two Sigma Investments, LP1.25M1.27%$743K+9%
Citadel Advisors LLC1.24M1.27%$741K+2522%
Geode Capital Management, LLC1.18M1.20%$703K-51%
Susquehanna International Group, LLP747,0390.76%$446K-14%
Millennium Management LLC656,0510.67%$392K-60%
Goldman Sachs Group Inc641,2080.65%$383K+126%
Vanguard Fiduciary Trust Co576,1250.59%$344K-12%
State Street Corp494,9510.50%$295K-72%
Marshall Wace, LLP368,1200.38%$221K+167%
XTX Topco Ltd226,6780.23%$135K+103%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ATYR insiders reported $50K of open-market purchases and $6.3K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$50K
1 trades, 1 people
Sales, 12 months
$6.3K
3 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
May 27, 2026
Filed May 28, 2026

Purchases and sales by month

$50K$50KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
May 27, 2026Paul SchimmelDirectorPurchase100,000$0.50$50KForm 4
Feb 4, 2026Sanjay ShuklaCEOSale3,745$0.98$3.7KForm 4
Feb 4, 2026Jill Marie BroadfootCFOSale1,558$0.98$1.5KForm 4
Feb 4, 2026Nancy DenyesGeneral CounselSale1,118$0.98$1.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Paul SchimmelDirector$50K–May 27, 2026
Sanjay ShuklaPresident and CEO, Director–$3.7KFeb 4, 2026
Jill Marie BroadfootChief Financial Officer–$1.5KFeb 4, 2026
Nancy DenyesGeneral Counsel–$1.1KFeb 4, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ATYR short interest

Low short interest. 0.3% of ATYR shares are sold short: about 1 share in 334. Over the last 12 reports the number of shares short went down 99%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 293,448 ATYR shares were sold short, 0.3% of the shares outstanding, down 97.1% from the report before. At the average daily volume of 87,073 shares, buying them all back would take about 3.4 trading days (days to cover).

Shares short, % of all shares

0.30%May 15Oct 3025.0%

Days to cover

3.4May 15Oct 3018.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026293,4480.30%-97%87,0733.4
Oct 15, 202610.27M10.47%-20%1.91M5.4
Sep 30, 202612.89M13.14%+21%13.42M1.0
Sep 15, 202610.67M10.88%+15%896,22911.9
Aug 31, 20269.28M9.46%-2%577,42116.1
Aug 14, 20269.44M9.63%-3%641,23214.7
Jul 31, 20269.73M9.92%+18%826,98811.8
Jul 15, 20268.28M8.44%-43%1.95M4.2
Jun 30, 202614.51M14.79%-22%2.86M5.1
Jun 15, 202618.51M18.88%-8%1.90M9.8
May 29, 202620.19M20.59%-6%4.03M5.0
May 15, 202621.39M21.82%+8%4.77M4.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

ATYR Pharma company events

ATYR Pharma filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (listing). The latest was on Nov 6, 2026.

  1. Nov 6, 2026AnnouncementATyr Pharma, Inc. filed a prospectus supplement related to the sale of the Company’s common stock, par value $0.001 per share with the Securities and Exchange Commission pursuant to which the Company may offer and sell Common Stock having an aggregate offering price of up to $79.99 million from… Filing
  2. Nov 5, 2026ResultsReleased financial results. Filing
  3. Oct 27, 2026RulesChanged its bylaws or articles. Filing
  4. Oct 16, 2026VoteReported shareholder vote results. Filing
  5. Sep 24, 2026AnnouncementATyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease… Filing
  6. Aug 7, 2026ResultsReleased financial results. Filing
  7. Jul 31, 2026AgreementEnded an important agreement. Filing
  8. Jun 8, 2026ListingAs previously disclosed, on December 4, 2025, aTyr Pharma, Inc. received a deficiency notice from the listing qualifications staff of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s… Filing
  9. Jun 1, 2026AnnouncementShared information with investors. Filing
  10. May 15, 2026ResultsReleased financial results. Filing
  11. May 11, 2026AnnouncementThe Company announced a regulatory and clinical update for its lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis, a major form of interstitial lung disease, following the receipt of the official meeting minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA). Filing
  12. Mar 5, 2026ResultsReleased financial results. Filing
  13. Dec 5, 2025ListingATyr Pharma, Inc. received a deficiency notice from the listing qualifications staff of The Nasdaq Stock Market LLC notifying the Company that, for the last 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below $1.00 per share… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

ATYR Pharma financials

Famous investors that hold ATYR

2 of the 50 well-known investors we track reported holding ATYR in their latest 13F filing. The largest position is Israel Englander's, worth $176K.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026581,272$176K0.0%-11%
Jim Simons · Renaissance TechnologiesQ3 2026281,522$85.3K0.0%+70%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ATYR in the last 120 days.

FiledHolderFormStake
Nov 4, 2026Federated Hermes, Inc.13G/A0.0%
Nov 4, 2026Federated Hermes, Inc.13G/A0.0%
Oct 7, 2026Federated Hermes, Inc.13G/A5.1%
Oct 7, 2026Federated Hermes, Inc.13G/A5.1%

Questions about aTYR PHARMA INC (ATYR) stock

Who owns the most ATYR stock?

The largest reported owner of aTYR PHARMA INC (ATYR) is Federated Hermes, Inc., with 8.7% of the company. In total, 89 funds and institutions reported holding ATYR at the end of Q2 2026, together about 41% of the shares. See the largest owners.

Are ATYR insiders buying or selling?

In the last 12 months, ATYR insiders reported 1 open-market purchase worth $50K and 3 sales worth $6.3K. The latest trade was on May 27, 2026. See every trade.

What is the short interest in ATYR?

As of Oct 30, 2026, 293,448 ATYR shares were sold short, 0.3% of the shares outstanding, down 97.1% from the report before. At the average daily volume of 87,073 shares, buying them all back would take about 3.4 trading days (days to cover). See the history.

Which famous investors hold ATYR?

2 of the 50 well-known investors we track reported ATYR in their latest 13F filing, including Israel Englander, Jim Simons. The largest position is worth $176K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.